Inhibitor Therapeutics (INTI) Director Michelle Yanez Receives Award

What Happened
Michelle Yanez, a director of Inhibitor Therapeutics, was granted 50,000 restricted common shares on May 4, 2026. The Form 4 reports an acquisition price of $0 (the award is compensation rather than an open-market purchase or sale). The grant is reported under the issuer's equity plan and is subject to shareholder approval.

Key Details

• Transaction date: 2026-05-04 (reported on Form 4 filed 2026-08-04).
• Transaction type: Award/Grant of restricted common stock (code A).
• Shares granted: 50,000; reported acquisition price: $0 (compensatory award).
• Shares owned after transaction: Not specified in the filing.
• Footnote: Represents restricted common stock issued pursuant to the Issuer's 2025 Equity Incentive Plan, subject to shareholder approval (Footnote F1).
• Timeliness: The Form 4 was filed nearly three months after the transaction date (filed 2026-08-04 for a 2026-05-04 grant), so this filing is late relative to the usual two-business-day requirement.

Context
Restricted stock awards are a form of compensation and do not necessarily indicate a purchase-driven bullish signal; they typically vest over time or upon shareholder approval and are used to align insiders' interests with shareholders. Because this award is subject to shareholder approval, its final issuance may depend on that vote. The late filing is an administrative detail investors should note but does not itself indicate the insider's market view.